First Report of Leaf Anthracnose Caused by on in China.

Tetrastigma hemsleyanum in the family Vitaceae, is a rare and endangered medicinal plant endemic in China (Ji et al. 2021). In October 2024, leaf anthracnose was observed in Lishui city (118°96'E, 28°13'N), Zhejiang, affecting T.

Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.

MSB2311 is a novel pH-dependent humanized anti-programmed death-ligand 1 (PD-L1) monoclonal antibody. This phase I study primarily aimed to determine the maximum tolerated dose (MTD)/recommended phase 2 dose level (RP2D) of MSB2311 in patients with advanced solid tumors or lymphoma. MSB2311 was intravenously administered at 3, 10, and 20 mg/kg every 3 weeks (Q3W) and 10 mg/kg every 2 weeks (Q2W) using 3 + 3 design.

Clinical effect and follow-up of laparoscopic radical proximal gastrectomy for upper gastric carcinoma.

Objective: To evaluate the safety and clinical effect of tubular esophagogastric anastomosis in laparoscopic radical proximal gastrectomy.

Methods: A retrospective analysis was conducted involving 191 patients who underwent laparoscopic radical proximal gastrectomy in the Department of Gastrointestinal Surgery, Qilu Hospital of Shandong University from January 2017 to October 2020. Patients were divided into tubular esophagogastric anastomosis group (TG group) and traditional esophagogastric anastomosis group (EG group) according to the digestive tract reconstruction.

Up-regulation of microRNA-183 reduces FOXO1 expression in gastric cancer patients with Helicobacter pylori infection.

The aim of the study is to detect the expression of FOXO1 mRNA and protein in samples from gastric cancer patients with Helicobacter pylori (H. pylori) infection, and to investigate the relationship between FOXO1 expression and miR-183 expression. Twenty-six gastric cancer patients with H.

First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.

Purpose: Aberrant activation of MET (hepatocyte growth factor receptor) signaling is implicated in the tumorigenesis of human cancers. This phase I study assessed the safety, tolerability, and MTD of the potent and selective MET inhibitor, savolitinib (AZD6094, HMPL-504, volitinib).

Patients And Methods: This open-label, multicenter dose-escalation and -expansion study evaluated oral savolitinib for patients with locally advanced or metastatic solid tumors.

Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.

Purpose: No antiangiogenic treatment is yet approved for extrapancreatic neuroendocrine tumors (NET). Surufatinib (HMPL-012, previously named sulfatinib) is a small-molecule inhibitor targeting vascular endothelial growth factor receptors, fibroblast growth factor receptor 1 and colony-stimulating factor 1 receptor. We conducted a single-arm phase Ib/II study of surufatinib in advanced NETs.

Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study.

Sulfatinib is a small molecule kinase inhibitor that targets tumor angiogenesis and immune modulation. This phase I study (NCT02133157) investigated the safety, pharmacokinetic characteristics, and preliminary anti-tumor activity of sulfatinib in patients with advanced solid tumors. The study included a dose-escalation phase (50-350 mg/day, 28-day cycle) with a Fibonacci (3+3) design, and a tumor-specific expansion phase investigating the tumor response to treatment.

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.

The efficacy and safety of bevacizumab with modified irinotecan, leucovorin bolus, and 5-fluorouracil intravenous infusion (mIFL) in the first-line treatment of metastatic colorectal cancer (mCRC) has not been well evaluated in randomized clinical trials in Chinese patients. We conducted a phrase III trial in which patients with previously untreated mCRC were randomized 2:1 to the mIFL [irinotecan (125 mg/m(2)), leucovorin (20 mg/m(2)) bolus, and 5-fluorouracil intravenous infusion (500 mg/m(2)) weekly for four weeks every six weeks] plus bevacizumab (5 mg/kg every two weeks) group and the mIFL group, respectively. Co-primary objectives were progression-free survival (PFS) and 6-month PFS rate.

A novel two-dimensional layered framework built of strontium(II) with 4-nitrobenzene-1,3-dicarboxylic acid.

In poly[[aquastrontium(II)]-micro(6)-4-nitrobenzene-1,3-dicarboxylato-kappa(7)O(1):O(2):O(2):O(3):O(3),O(4):O(4)], [Sr(C(8)H(3)NO(6))(H(2)O)](n), the Sr(II) ion displays a distorted bicapped triangular prismatic configuration, defined by seven carboxyl O atoms from six symmetry-related ligands and one water molecule. The ligand molecules connect the Sr(II) ions into a two-dimensional layered framework in the ac plane, with close O..

Tetraaquabis(5-carboxy-2-nitrobenzoato-kappaO)manganese(II) dihydrate: a metal-water chain complex containing cyclic water tetramers.

In the title complex, [Mn(C(8)H(4)NO(6))(2)(H(2)O)(4)] x 2H(2)O, cyclic water tetramers forming one-dimensional metal-water chains have been observed. The water clusters are trapped by the co-operative association of coordination interactions and hydrogen bonds. The Mn(II) ion resides on a center of symmetry and is in an octahedral coordination environment comprising two O atoms from two 5-carboxy-2-nitrobenzoate ligands and four O atoms from water molecules.

Bis(mu-3-nitrobenzene-1,2-dicarboxylato)-kappa8O1,O2:O2,O3;O3,O2:O2,O1-bis[triaqua(2-carboxy-3-nitrobenzoato-kappa2O,O')lanthanum(III)] dihydrate.

The title compound, [La2(C8H3NO6)2(C8H4NO6)2(H2O)6].2H2O, consists of dimeric units related by an inversion center. The two La(III) atoms are linked by two bridging bidentate carboxylate groups and two monodentate carboxylate groups.